Nkarta, Inc. (NASDAQ: NKTX) is a Healthcare company (Biotechnology) with a market capitalization of $90M. The Maz Rating grades it against the other companies in its sector.
Nkarta, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.25, Nkarta, Inc. trades at 0.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -48.6%, return on invested capital of -48.9% and a free cash flow yield of -118.0%. On the balance sheet: a debt-to-equity ratio of 0.33 and a current ratio of 5.79. Over the past 52 weeks the share price ranged from $1.10 to $3.72, with a beta of 0.97.
Nkarta, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 1 Strong Buy, 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.